The Migraine Treatment Journey in US Veterans: A National Cohort Study of Prescribing Patterns

INTRODUCTION: Migraine in veterans is poorly understood due to limited real-world treatment data. This study aimed to characterize pharmacotherapeutic pathways for US veterans with migraine and evaluate the impact of care setting on therapy progression. METHODS: This was a national, population-based, retrospective cohort study utilizing deidentified electronic health record data between January 2019 and June 2024 extracted from the Veterans Affairs Corporate Data Warehouse. Eligible patients were aged > 18 years with at least one diagnosis of migraine (ICD-10: G43.x) or one migraine-specific medication. The primary objective was to describe treatment patterns for veterans. Differences between primary care (PC) and specialty care (SC) were assessed using subdistribution hazard ratios (sHR). RESULTS: Of 285,509 patients with newly diagnosed migraine, 252,661 (88.5%) received pharmacologic treatment and 150,684 (59.6%) received ≥ 1 preventive medication. The median (25th-75th percentile) number of treatment sequence steps was two (1-2), with a median time of 3 (0-40) days between diagnosis and initial treatment steps and 72 (5-295) days between subsequent treatment steps. For patients who received preventive medication, the median number of treatment sequence steps was one (1-2), with a median time from diagnosis to initial treatment steps of 46 (5-225) days and 128 (28-418) days between subsequent treatment steps. Of patients who received preventive medications, 91,793 (60.9%) received care from a PC provider only, and 21,268 (14.1%) from a SC provider only. Veterans receiving care within SC settings were > 50% more likely to transition to a second sequential step of preventive treatment (sHR 1.54 [95% CI 1.51-1.58]) and > six times more likely to initiate preventive calcitonin gene-related peptide (CGRP) antagonists (sHR 6.43 [95% CI 5.94-6.97]). CONCLUSIONS: Most veterans with migraine received pharmacologic treatment. Intervals for initiating and transitioning preventive therapies were longer than recommended by guidelines. Veterans under SC were more likely to progress through preventive therapies, including CGRP antagonists, than those in PC.

Authors

Institutions

Publication Details

Journal
Pain and Therapy
Published
2026-11-13
DOI
https://doi.org/10.1007/s40122-026-00898-9
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Migraine Treatment Journey in US Veterans: A National Cohort Study of Prescribing Patterns

Nathan Spence, John O. Spain, Jon J. Glover, Feng Dai et al.
2 links
Pain and Therapy
Migraine and Headache Studies
article

The Migraine Treatment Journey in US Veterans: A National Cohort Study of Prescribing Patterns

Nathan Spence, John O. Spain, Jon J. Glover, Feng Dai, Carlos A. Álvarez, Christine Vu, Aaron Rode Perkins, Avani Patel, Hui Yang, James Kenneth Murtha
article en

Abstract

INTRODUCTION: Migraine in veterans is poorly understood due to limited real-world treatment data. This study aimed to characterize pharmacotherapeutic pathways for US veterans with migraine and evaluate the impact of care setting on therapy progression. METHODS: This was a national, population-based, retrospective cohort study utilizing deidentified electronic health record data between January 2019 and June 2024 extracted from the Veterans Affairs Corporate Data Warehouse. Eligible patients were aged > 18 years with at least one diagnosis of migraine (ICD-10: G43.x) or one migraine-specific medication. The primary objective was to describe treatment patterns for veterans. Differences between primary care (PC) and specialty care (SC) were assessed using subdistribution hazard ratios (sHR). RESULTS: Of 285,509 patients with newly diagnosed migraine, 252,661 (88.5%) received pharmacologic treatment and 150,684 (59.6%) received ≥ 1 preventive medication. The median (25th-75th percentile) number of treatment sequence steps was two (1-2), with a median time of 3 (0-40) days between diagnosis and initial treatment steps and 72 (5-295) days between subsequent treatment steps. For patients who received preventive medication, the median number of treatment sequence steps was one (1-2), with a median time from diagnosis to initial treatment steps of 46 (5-225) days and 128 (28-418) days between subsequent treatment steps. Of patients who received preventive medications, 91,793 (60.9%) received care from a PC provider only, and 21,268 (14.1%) from a SC provider only. Veterans receiving care within SC settings were > 50% more likely to transition to a second sequential step of preventive treatment (sHR 1.54 [95% CI 1.51-1.58]) and > six times more likely to initiate preventive calcitonin gene-related peptide (CGRP) antagonists (sHR 6.43 [95% CI 5.94-6.97]). CONCLUSIONS: Most veterans with migraine received pharmacologic treatment. Intervals for initiating and transitioning preventive therapies were longer than recommended by guidelines. Veterans under SC were more likely to progress through preventive therapies, including CGRP antagonists, than those in PC.

Pain and Therapy
Texas Tech University (US), Pfizer (United States) (US), Texas Tech University Health Sciences Center (US)
Pfizer
Good health and well-being
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon